The seed round was backed by private investors establishing QantX Ventures to fund clinical development.
"We are excited to become part of the Neuronostics journey, they have pioneered innovative technology that will make a significant positive difference to the lives of many people around the world."
Triple Point Ventures led the pre-series A round, which will help expand the company's platform across the UK and Europe.
"At GripAble, we know this market better than anyone and understand that any solution must be therapist driven and must allow them to engage and empower their patients to self-manage beyond standard therapy hours. This need for remote therapy has been greatly accelerated by COVID-19."